Choose BENLYSTA now for your pediatric patients with lupus nephritis

BENLYSTA is the first and only FDA-approved biologic for patients ≥5 years with lupus nephritis

Explore the data

Find out more

BENLYSTA is designed to target BLyS, an underlying cause of lupus and lupus nephritis1,2

Find out more

Icon: Renal

Characteristics of lupus nephritis

Find out more

Starting a patient on BENLYSTA

Find out more

See the administration options for BENLYSTA

Find out more

Calculate the number of vials needed for your pediatric patients

Find out more

See the long-term safety data for BENLYSTA observed over 7 years in adult patients with lupus3

Find out more

Learn more

Identifying the BENLYSTA patient

Patient profiles to help you determine which of your patients may benefit from BENLYSTA.

Find out more

Safety profile

Well-established safety profile based on the largest clinical trial program in lupus and lupus nephritis.

Find out more

Choose BENLYSTA today for your pediatric patients with lupus nephritis

Choose BENLYSTA today for your pediatric patients with lupus nephritis